Six verified stories from this week, in plain English, with the honest caveats left in. The GLP-1 eye warning, in proportion. On 9 November the United States Food and Drug Administration required every GLP-1 receptor agonist to add NAION, a rare form of sudden painless vision loss in one eye, to the Warnings and Precautions section of its label. That covers semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and orforglipron. The numbers deserve proportion. Across 126 clinical trials covering 134,253 patients there were 15 probable cases, 10 on a GLP-1 and 5 on placebo, which works out to 6.4 cases per 100,000 person years against 3.8. In real world data, GLP-1 starters had a higher rate than people starting a DPP-4 inhibitor, hazard ratio 1.43, barely clearing significance, and no significant difference against SGLT2 inhibitors. The regulator used the word potential, animal studies found no mechanism, and people on these drugs already carry the risk factors for optic nerve damage. If you lose vision suddenly and painlessly in one eye, seek help the same day, and do not stop your medication on your own. A world first for type 1 diabetes. On 14 November, World Diabetes Day, the World Health Organization published its first ever guideline on diagnosing and managing type 1 diabetes in adults. It recommends multiple daily insulin injections adjusted to blood glucose, names human insulin as an appropriate and effective option, and recommends regular monitoring, with urine glucose testing considered where no other testing exists. About 9.5 million people were living with type 1 diabetes worldwide in 2025, with roughly 500,000 newly diagnosed. The caveat: a guideline does not by itself put insulin in a pharmacy. A pill that improved sleep apnea. Published in JAMA on 9 November, two phase 3 trials of orforglipron in 712 adults with moderate to severe obstructive sleep apnea and excess weight. Over 52 weeks, breathing interruptions fell by about 18 events an hour on the tablet against 4.5 on placebo in people not using a breathing machine, and about 17 against 5 in those already using one. Weight loss was around 10 percent. Caveat: stomach side effects affected roughly 7 in 10 people, follow-up was one year, and nothing here shows it replaces a breathing machine. A new kind of blood thinner for stroke. Also on 9 November, the FDA approved asundexian, sold as Sunharbo, the first factor XIa inhibitor, for adults after a recent non-cardioembolic ischemic stroke or high risk TIA who are already on antiplatelet therapy. In OCEANIC-STROKE it cut ischemic strokes by about 26 percent in relative terms and about 2 percentage points in absolute terms over two years, without an increase in major bleeding. Caveat: the absolute benefit is modest, it is not approved for atrial fibrillation, and the list price is around 750 dollars a month. A safety result, not a victory lap. In The Lancet on 9 November, SYNCHRONIZE-CVOT tested survodutide in 5,530 adults with obesity or overweight plus cardiovascular disease, kidney disease or risk factors. It met its cardiovascular safety endpoint, with weight loss up to about 13.7 percent at 72 weeks against 2 percent on placebo. The caveat matters: the trial was designed to rule out harm, not to prove heart benefit, and the confidence interval is too wide to tell those apart. About 1 in 5 stopped because of stomach side effects, and the drug is not approved anywhere yet. A tubeless insulin pump. On 13 November the FDA cleared a tubeless cartridge and infusion set for the Tandem Mobi, so the same pump can be worn with or without tubing for up to seven days. Caveat: this is a hardware clearance, not new outcome data, and it is not expected to be available until the first half of 2027. The one habit to take away: if you live with diabetes, book a dilated eye examination and keep it on a yearly rhythm. Most sight threatening diabetic eye disease causes no symptoms until it is advanced. One reminder. This is general education, not personal medical advice. Please talk to your own clinician about your care. Topics: diabetes, type 1 diabetes, type 2 diabetes, GLP-1, semaglutide, tirzepatide, orforglipron, NAION, vision loss, eye health, diabetic retinopathy, obesity, sleep apnea, stroke, insulin pump, FDA, World Health Organization, medical news